|
| Primary information |
|---|
| ID | 10689 |
| Therapeutic ID | Th1153 |
| Protein Name | Alefacept |
| Sequence | >Th1153_Alefacept
CFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSNRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYVDGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
|
| Molecular Weight | 51801.1 |
| Chemical Formula | C2306H3594N610O694S26 |
| Isoelectric Point | 7.86 |
| Hydrophobicity | -0.432 |
| Melting point | NA |
| Half-life | 270 hrs |
| Description | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. |
| Indication/Disease | As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis |
| Pharmacodynamics | Interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes. |
| Mechanism of Action | Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen. |
| Toxicity | While it has been found to cross the placenta in monkeys, it is not yet known if it also diffuses into breast milk. |
| Metabolism | NA |
| Absorption | Bioavailability after IM administration is 63%. |
| NA |
| Clearance | NA |
| Categories | Dermatologic and Immunosupressive agents |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Canakinumab, Rilonacept- Increases immunosupressive effects |
| Target | T-cell surface antigen CD2,Low affinity immunoglobulin gamma Fc region receptor III-A,Low affinity immunoglobulin gamma Fc region receptor III-B |
| Brand Name | Amevive |
| Company | Astellas Pharma Inc. |
| Brand Description | Astellas Pharma Inc. |
| Prescribed For | AMEVIVE is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. |
| Chemical Name | NA |
| Formulation | It contains alefacept (15 mg), citric acid monohydrate (0.06 mg), glycine (5 mg), sodium citrate dehydrate (3.6 mg), and sucrose (12.5 mg) per 0.5 mL of reconstituted solution. |
| Physical Appearance | AMEVIVE is supplied as a sterile, white-to-off-white, preservative-free, lyophilized powder |
| Route of Administration | Intramuscular Injection |
| Recommended Dosage | The recommended dose of AMEVIVE® is 15 mg intramuscularly once weekly for 12 weeks. The CD4+ T lymphocyte counts should be measured before initiating dosing. |
| Contraindication | AMEVIVE should not be administered to patients infected with HIV. AMEVIVE reduces CD4+ T lymphocyte counts, which might accelerate disease progression or increase complications of disease in these patients |
| Side Effects | Lymphopenia, Malignancies, Serious Infections reuiring hospitalization, Hypersenstivity reactions. |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |